According to Avid Bioservices 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -149.32. At the end of 2022 the company had a P/E ratio of 7.17.
Year | P/E ratio | Change |
---|---|---|
2022 | 7.17 | -96.8% |
2021 | 224 | -294.51% |
2020 | -115 | 170.82% |
2019 | -42.6 | 274.15% |
2018 | -11.4 | 137.76% |
2017 | -4.79 | 213.46% |
2016 | -1.53 | -61.38% |
2015 | -3.96 | -23.15% |
2014 | -5.15 | -25.93% |
2013 | -6.95 | 100.08% |
2012 | -3.47 | 88.86% |
2011 | -1.84 | -63.21% |
2010 | -5.00 | -56.08% |
2009 | -11.4 | 253.32% |
2008 | -3.22 | -4.2% |
2007 | -3.36 | -68.1% |
2006 | -10.5 | 36.07% |
2005 | -7.75 | -27.14% |
2004 | -10.6 | -56.68% |
2003 | -24.6 | 340.74% |
2002 | -5.57 | -88.63% |
2001 | -49.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Neogen NEOG | -102 | -31.91% | ๐บ๐ธ USA |
Natera NTRA | -18.7 | -87.45% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.